Law Offices of Howard G. Smith reminds investors that all purchasers of the common stock of Endocyte, Inc. (“Endocyte” or the “Company”) (NASDAQ:ECYT) between March 21, 2014 and May 2, 2014, inclusive (the “Class Period”) have until August 25, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.

Endocyte is a biopharmaceutical company engaged in the development of targeted therapies for the treatment of cancer and inflammatory diseases. The Complaint alleges that the defendants issued misleading statements during the Class Period regarding the efficacy of Endocyte's experimental drug VYNFINIT®. On May 2, 2014, Endocyte disclosed that VYNFINIT was found ineffective in the treatment of platinum-resistant ovarian cancer, based on certain testing methods known as response evaluation criteria in solid tumors, or “RECIST.” The Company subsequently announced that it would withdraw its application to market VYNFINIT in Europe.

If you are a member of the Class described above, you may move the Court no later than August 25, 2014, to serve as lead plaintiff, if you meet certain legal requirements. To be a member of the Class, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.